Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929884 | 0.93 | TOP2A (0.48) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL9688633 | 0.92 | CACNA1F (0.49) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL9585893 | 0.90 | STAT3 (0.54) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5704330 | 0.90 | ADRB2 (0.49) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL1344898 | 0.90 | STAT3 (0.54) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL7577114 | 0.89 | ADRB2 (0.47) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL6880793 | 0.87 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL1344612 | 0.86 | GSK3B (0.49) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL9133982 | 0.85 | ADRB2 (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5704411 | 0.83 | GSK3B (0.66) | GSK3BTOP2ATOP2BCACNA1FPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319656-B1 | A NEW PROCESS FOR PREPARING A QUINOLONE-CARBOXYLIC ACID | LYNCHEM CO LTD (CN) | 2006-08-23 | — | — | EP | disclosed |
| US-6699992-B2 | REACTING M-FLUOROACETOPHENONE COMPOUND WITH ALKYL CARBONATE; REACTING ESTER OBTAINED WITH ALKYL ORTHOFORMATE AND AMINE; CYCLIZATION IN BASE | LYNCHEM CO., LTD. (CN) | 2004-03-02 | — | — | US | disclosed |
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | LYNCHEM CO., LTD. (CN) | 2003-09-04 | — | — | US | disclosed |
| EP-1319656-A1 | A NEW PROCESS FOR PREPARING A QUINOLONE-CARBOXYLIC ACID | Lynchem Co., Ltd. (CN) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | CYP4B1, QPCT, NQO2 | GSK3B 4162/4885TOP2A 601/4885TOP2B 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.